270 related articles for article (PubMed ID: 25978039)
1. The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.
Gervas-Arruga J; Cebolla JJ; de Blas I; Roca M; Pocovi M; Giraldo P
PLoS One; 2015; 10(5):e0126153. PubMed ID: 25978039
[TBL] [Abstract][Full Text] [Related]
2. Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1.
Zimmermann A; Popp RA; Rossmann H; Bucerzan S; Nascu I; Leucuta D; Weber MM; Grigorescu-Sido P
Ther Clin Risk Manag; 2018; 14():2069-2080. PubMed ID: 30498352
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease: a study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Khan A; Hangartner T; Weinreb NJ; Taylor JS; Mistry PK
J Bone Miner Res; 2012 Aug; 27(8):1839-48. PubMed ID: 22692814
[TBL] [Abstract][Full Text] [Related]
4. Ferritinemia and serum inflammatory cytokines in Swedish adults with Gaucher disease type 1.
Lorenz F; Pawłowicz E; Klimkowska M; Beshara S; Bulanda Brustad A; Skotnicki AB; Wahlin A; Machaczka M
Blood Cells Mol Dis; 2018 Feb; 68():35-42. PubMed ID: 27816428
[TBL] [Abstract][Full Text] [Related]
5. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
6. In vitro osteoclastogenesis from Gaucher patients' cells correlates with bone mineral density but not with Chitotriosidase.
Bondar C; Mucci J; Crivaro A; Ormazabal M; Ceci R; Oliveri B; González D; Rozenfeld P
Bone; 2017 Oct; 103():262-269. PubMed ID: 28736246
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation.
Herrera S; Pérez-López J; Moltó-Abad M; Güerri-Fernández R; Cabezudo E; Novelli S; Esteve J; Hernández A; Roig I; Solanich X; Prieto-Alhambra D; Nogués X; Díez-Pérez A
J Bone Miner Res; 2017 Jul; 32(7):1575-1581. PubMed ID: 28263001
[TBL] [Abstract][Full Text] [Related]
8. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.
Lo SM; Stein P; Mullaly S; Bar M; Jain D; Pastores GM; Mistry PK
Am J Hematol; 2010 May; 85(5):340-5. PubMed ID: 20425796
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
Weinreb NJ; Finegold DN; Feingold E; Zeng Z; Rosenbloom BE; Shankar SP; Amato D
Orphanet J Rare Dis; 2015 May; 10():64. PubMed ID: 25994334
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.
Laudemann K; Moos L; Mengel KE; Lollert A; Reinke J; Brixius-Huth M; Wagner D; Düber C; Staatz G
Rofo; 2015 Dec; 187(12):1093-8. PubMed ID: 26200566
[TBL] [Abstract][Full Text] [Related]
11. Bone complications in children with Gaucher disease.
Bembi B; Ciana G; Mengel E; Terk MR; Martini C; Wenstrup RJ
Br J Radiol; 2002; 75 Suppl 1():A37-44. PubMed ID: 12036831
[TBL] [Abstract][Full Text] [Related]
12. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
13. Patients with type 1 Gaucher disease in Spain: A cross-sectional evaluation of health status.
Giraldo P; Pérez-López J; Núñez R; de la Puebla RF; Luño E; Saura-Grau S; Bureo JC; Plaza S; de la Serna J
Blood Cells Mol Dis; 2016 Jan; 56(1):23-30. PubMed ID: 26603719
[TBL] [Abstract][Full Text] [Related]
14. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.
Drugan C; Jebeleanu G; Grigorescu-Sido P; Caillaud C; Craciun AM
Blood Cells Mol Dis; 2002; 28(1):13-20. PubMed ID: 11814307
[TBL] [Abstract][Full Text] [Related]
15. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
Benedik-Dolničar M; Kitanovski L
Pediatr Int; 2011 Dec; 53(6):1018-22. PubMed ID: 21883686
[TBL] [Abstract][Full Text] [Related]
16. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
17. Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density.
Arnheim E; Chicco G; Phillips M; Lebel E; Foldes AJ; Itzchaki M; Elstein D; Zimran A; Altarescu G
Rheumatol Int; 2008 Jul; 28(9):873-7. PubMed ID: 18317771
[TBL] [Abstract][Full Text] [Related]
18. The modulation of inflammatory parameters, Brain-derived neurotrophic factor levels and global histone H4 acetylation status in peripheral blood of patients with Gaucher disease type 1.
de Mello AS; da Silva IR; Reinaldo GP; Dorneles GP; Cé J; Lago PD; Peres A; Elsner VR; Coelho JC
Clin Biochem; 2017 Mar; 50(4-5):228-233. PubMed ID: 27865783
[TBL] [Abstract][Full Text] [Related]
19. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease.
Todhunter CE; Sutherland-Craggs A; Bartram SA; Donaldson PT; Daly AK; Francis RM; Mansfield JC; Thompson NP
Gut; 2005 Nov; 54(11):1579-84. PubMed ID: 16009674
[TBL] [Abstract][Full Text] [Related]
20. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
